Literature DB >> 28844436

Psychosis subgroups differ in intrinsic neural activity but not task-specific processing.

Matthew E Hudgens-Haney1, Lauren E Ethridge2, Jennifer E McDowell3, Sarah K Keedy4, Godfrey D Pearlson5, Carol A Tamminga6, Matcheri S Keshavan7, John A Sweeney8, Brett A Clementz9.   

Abstract

Individuals with psychosis often show high levels of intrinsic, or nonspecific, neural activity, but attenuated stimulus-specific activity. Clementz et al. (2016) proposed that one subgroup of psychosis cases has accentuated intrinsic activity (Biotype-2's) and a different subgroup (Biotype-1's) has diminished intrinsic activity, with both groups exhibiting varying degrees of cognitive deficits. This model was studied by assessing neural activity in psychosis probands (N=105) during baseline and a 5second period in preparation for a pro-/anti-saccade task. Steady-state stimuli allowed real-time assessment of modulation of visuocortical investment to different target locations. Psychosis probands as a whole showed poor antisaccade performance. As expected, Biotype-1 showed diminished intrinsic neural activity and the worst behavior, and Biotype-2 showed accentuated intrinsic activity and less deviant behavior. Both of these groups also exhibited less dynamic oscillatory phase synchrony. Biotype-3 showed no neurophysiological differences from healthy individuals, despite a history of psychosis. Interestingly, all psychosis subgroups showed normal (i.e., not different from healthy) preparatory modulation of visuocortical investment as a function of cognitive demands, despite varying levels of task performance. Similar analyses conducted subgrouping cases by psychotic symptomatology revealed fewer and less consistent differences, including no intrinsic activity differences between any clinical subgroup and healthy individuals. This study illustrates that (i) differences in intrinsic neural activity may be a fundamental characteristic of psychosis and need to be evaluated separately from stimulus-specific responses, and (ii) grouping patients based on multidimensional classification using neurobiological data may have advantages for resolving heterogeneity and clarifying illness mechanisms relative to traditional psychiatric diagnoses.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Biomarkers; Bipolar disorder; EEG; Psychosis; Schizophrenia; Steady-state

Mesh:

Year:  2017        PMID: 28844436      PMCID: PMC5826774          DOI: 10.1016/j.schres.2017.08.023

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  45 in total

1.  Neural synchrony indexes disordered perception and cognition in schizophrenia.

Authors:  Kevin M Spencer; Paul G Nestor; Ruth Perlmutter; Margaret A Niznikiewicz; Meredith C Klump; Melissa Frumin; Martha E Shenton; Robert W McCarley
Journal:  Proc Natl Acad Sci U S A       Date:  2004-11-16       Impact factor: 11.205

2.  Neural activity in monkey prefrontal cortex is modulated by task context and behavioral instruction during delayed-match-to-sample and conditional prosaccade-antisaccade tasks.

Authors:  Kevin Johnston; Stefan Everling
Journal:  J Cogn Neurosci       Date:  2006-05       Impact factor: 3.225

3.  Schizophrenia: reduced signal-to-noise ratio and impaired phase-locking during information processing.

Authors:  G Winterer; M Ziller; H Dorn; K Frick; C Mulert; Y Wuebben; W M Herrmann; R Coppola
Journal:  Clin Neurophysiol       Date:  2000-05       Impact factor: 3.708

4.  Synaptic proteins in the hippocampus indicative of increased neuronal activity in CA3 in schizophrenia.

Authors:  Wei Li; Subroto Ghose; Kelly Gleason; Anita Begovic; Jessica Perez; John Bartko; Scott Russo; Anthony D Wagner; Lynn Selemon; Carol A Tamminga
Journal:  Am J Psychiatry       Date:  2015-01-13       Impact factor: 18.112

5.  Event-related potential and time-frequency endophenotypes for schizophrenia and psychotic bipolar disorder.

Authors:  Lauren E Ethridge; Jordan P Hamm; Godfrey D Pearlson; Carol A Tamminga; John A Sweeney; Matcheri S Keshavan; Brett A Clementz
Journal:  Biol Psychiatry       Date:  2014-05-04       Impact factor: 13.382

6.  A pharmacological model for psychosis based on N-methyl-D-aspartate receptor hypofunction: molecular, cellular, functional and behavioral abnormalities.

Authors:  Dan Rujescu; Andreas Bender; Martin Keck; Annette M Hartmann; Frauke Ohl; Hanna Raeder; Ina Giegling; Just Genius; Robert W McCarley; Hans-Jürgen Möller; Heinz Grunze
Journal:  Biol Psychiatry       Date:  2006-01-19       Impact factor: 13.382

7.  Intrinsic neural activity differences among psychotic illnesses.

Authors:  Matthew E Hudgens-Haney; Lauren E Ethridge; Justin B Knight; Jennifer E McDowell; Sarah K Keedy; Godfrey D Pearlson; Carol A Tamminga; Matcheri S Keshavan; John A Sweeney; Brett A Clementz
Journal:  Psychophysiology       Date:  2017-04-17       Impact factor: 4.016

Review 8.  Neurophysiology and neuroanatomy of reflexive and volitional saccades: evidence from studies of humans.

Authors:  Jennifer E McDowell; Kara A Dyckman; Benjamin P Austin; Brett A Clementz
Journal:  Brain Cogn       Date:  2008-10-05       Impact factor: 2.310

Review 9.  Computational models of schizophrenia and dopamine modulation in the prefrontal cortex.

Authors:  Edmund T Rolls; Marco Loh; Gustavo Deco; Georg Winterer
Journal:  Nat Rev Neurosci       Date:  2008-09       Impact factor: 34.870

10.  Clinical phenotypes of psychosis in the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP).

Authors:  Carol A Tamminga; Elena I Ivleva; Matcheri S Keshavan; Godfrey D Pearlson; Brett A Clementz; Bradley Witte; David W Morris; Jeffrey Bishop; Gunvant K Thaker; John A Sweeney
Journal:  Am J Psychiatry       Date:  2013-11       Impact factor: 18.112

View more
  3 in total

1.  Cognitive Impairment and Diminished Neural Responses Constitute a Biomarker Signature of Negative Symptoms in Psychosis.

Authors:  Matthew E Hudgens-Haney; Brett A Clementz; Elena I Ivleva; Matcheri S Keshavan; Godfrey D Pearlson; Elliot S Gershon; Sarah K Keedy; John A Sweeney; Florence Gaudoux; Pierre Bunouf; Benoit Canolle; Françoise Tonner; Silvia Gatti-McArthur; Carol A Tamminga
Journal:  Schizophr Bull       Date:  2020-02-11       Impact factor: 9.306

2.  Psychosis Biotypes: Replication and Validation from the B-SNIP Consortium.

Authors:  Brett A Clementz; David A Parker; Rebekah L Trotti; Jennifer E McDowell; Sarah K Keedy; Matcheri S Keshavan; Godfrey D Pearlson; Elliot S Gershon; Elena I Ivleva; Ling-Yu Huang; S Kristian Hill; John A Sweeney; Olivia Thomas; Matthew Hudgens-Haney; Robert D Gibbons; Carol A Tamminga
Journal:  Schizophr Bull       Date:  2022-01-21       Impact factor: 9.306

3.  A Diagnosis and Biotype Comparison Across the Psychosis Spectrum: Investigating Volume and Shape Amygdala-Hippocampal Differences from the B-SNIP Study.

Authors:  Synthia Guimond; Feng Gu; Holly Shannon; Sinead Kelly; Luke Mike; Gabriel A Devenyi; M Mallar Chakravarty; John A Sweeney; Godfrey Pearlson; Brett A Clementz; Carol Tamminga; Matcheri Keshavan
Journal:  Schizophr Bull       Date:  2021-10-21       Impact factor: 7.348

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.